Carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a breakdown product of type I collagen mediated by matrix metalloproteinases (MMPs), the serum level of which not only indicates the degradation rate of type I collagen and the destruction degree of bone matrix, but also is served as a specific marker reflecting bone resorption. Creative BioMart Biomarker offers high quality detection service for ICTP, ensuring high detection accuracy, sensitivity and efficiency for each sample.
Introduction
ICTP is a trivalent cross-linked telopeptide with a large conformational epitope. Type I collagen is the most abundant collagen in the human body and is an important component of bone, which accounts for about 90% of the organic part of bone matrix. In bone, a type I collagen molecule is cross-linked by three residues of hydroxylysine, lysine or a derivative thereof to form a fluorescent cyclic pyridinium structure and an unidentified non-fluorescent structure that links three different collagen polypeptide chains together. Type I collagen is mainly degraded by two ways. The first is the intracellular pathway, which is catalyzed by cathepsin K to produce carboxy-terminal collagen I crosslinks (CTX-I) and amino-terminal collagen crosslinks (NTX), etc. The second is the extracellular pathway that is mediated by MMPs and produces ICTP. Both ICTP and CTX-I are derived from the carboxy-terminal of type I collagen and are very sensitive and specific markers of bone resorption. However, their production is mediated by different enzymes. When the bone changes pathologically, ICTP will enter the blood in the form of intact immunogenic peptide without further decomposition, so it can directly reflect the range and degree of pathological bone destruction, and is not subject to food intake and the physiological cycle. Furthermore, ICTP exhibits its unique sensitivity, specificity, and accuracy in the diagnosis of bone metastases. Many studies have indicated that malignancy patients with bone metastases had increased serum ICTP levels to varying degrees. It can not only directly reflect whether bone metastasis has occurred, but also reflect the degree of bone involvement and the degree of bone pain, and provide some valuable information for the prognosis of patients.
Figure 1. Type I collagen structure (Nielsen, et al. 2019)
Application of ICTP Detection
- Serum ICTP level as a biomarker to predict different diseases, such as bone metastases, rheumatoid arthritis, multiple myeloma, etc.
Our Advantages
- Guarantee high accuracy and sensitivity for ICTP detection
- Ensure high repeatability of ICTP detection
- Short turn-around time of detection service
- Competitive price in the market of detection services
- Provide multiple ICTP detection methods, including ELISA, EIA and RIA
- Accept a wide range of sample types (serum, plasma, tissue homogenate, etc.)
Workflow of ICTP Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the ICTP detection procedure to ensure accurately quantify the level of ICTP in each sample.
At Creative BioMart Biomarker, we offer ICTP detection service that includes several technical methods, you can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Terpos, E. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the international myeloma working group. Leukemia. 2010, 24(10): 1700-1712.
- Fardellone, P.; et al. Bone remodeling markers in rheumatoid arthritis. Mediators of Inflammation. 2014, 2014: 1-5.
- Nielsen, M.J.; et al. (2019) Extracellular Matrix remodeling with focus on biochemical markers in liver fibrosis: limitations and possibilities. Krag, A.; Hansen, T. (Eds.). The human gut-liver-axis in health and disease (pp. 265-286). Cham: Springer Nature Switzerland AG.
- Bertoldo, F. (2017). Markers of Bone Turnover in Bone Metastasis from Prostate Cancer. Bertoldo, F.; et al. (Eds.), Bone Metastases from Prostate Cancer (pp. 13-23). Cham: Springer International Publishing Switzerland.
